Search Results - "Pang, P.S" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Genome‐wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID‐19

Genome‐wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID‐19

by Corley, Michael J., Pang, Alina P.S., Dody, Kush, Mudd, Philip A., Patterson, Bruce K., Seethamraju, Harish, Bram, Yaron, Peluso, Michael J., Torres, Leonel, Iyer, Nikita S., Premeaux, Thomas A., Yeung, Stephen T., Chandar, Vasuretha, Borczuk, Alain, Schwartz, Robert E., Henrich, Timothy J., Deeks, Steven G., Sacha, Jonah B., Ndhlovu, Lishomwa C.
Published in Journal of Leukocyte Biology (01.07.2021)

Get full text

Journal Article Web Resource

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

by Patterson, Bruce K., Seethamraju, Harish, Dhody, Kush, Corley, Michael J., Kazempour, Kazem, Lalezari, Jay, Pang, Alina P.S., Sugai, Christopher, Mahyari, Eisa, Francisco, Edgar B., Pise, Amruta, Rodrigues, Hallison, Wu, Helen L., Webb, Gabriela M., Park, Byung S., Kelly, Scott, Pourhassan, Nader, Lelic, Alina, Kdouh, Lama, Herrera, Monica, Hall, Eric, Bimber, Benjamin N., Plassmeyer, Matthew, Gupta, Raavi, Alpan, Oral, O’Halloran, Jane A., Mudd, Philip A., Akalin, Enver, Ndhlovu, Lishomwa C., Sacha, Jonah B.
Published in International journal of infectious diseases (01.02.2021)

Get full text

Journal Article

O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE

O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE

by Gane, E.J, Hyland, R.H, An, D, Pang, P.S, Symonds, W.T, Mchutchison, J.G, Stedman, C.A
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection

O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection

by Abergel, A, Loustaud-Ratti, V, Metivier, S, Jiang, D, Kersey, K, Knox, S.J, Pang, P.S, Samuel, D, Asselah, T
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks

O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks

by Lawitz, E, Flamm, S, Yang, J.C, Pang, P.S, Zhu, Y, Svarovskaia, E, McHutchison, J.G, Wyles, D, Pockros, P
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY

by Gane, E.J, Stedman, C.A, Hyland, R.H, Pang, P.S, Ding, X, Symonds, W.T, McHutchison, J.G
Published in Journal of hepatology (01.04.2013)

Get full text

Journal Article

1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938

1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938

by Guedj, J, Pang, P.S, Lawitz, E, Rodriguez-Torres, M, Symonds, B, Perelson, A.S
Published in Journal of hepatology (01.04.2013)

Get full text

Journal Article

P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial

P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial

by Welzel, T.W, Reddy, K.R, Flamm, S.L, Denning, J, Arterburn, S, Brandt-Sarif, T, Pang, P.S, McHutchison, J.G, Charlton, M, Everson, G.T, Zeuzem, S, Afdhal, N
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials

P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials

by Samuel, D, Manns, M, Forns, X, Flamm, S.L, Reddy, K.R, Denning, J, Arterburn, S, Brandt-Sarif, T, Pang, P.S, McHutchison, J.G, Afdhal, N, Charlton, M, Gane, E, Mutimer, D, Everson, G.T
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation

P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation

by Forns, X, Mutimer, D, Manns, M, Reddy, K.R, Everson, G.T, Flamm, S.L, Denning, J, Arterburn, S, Brandt-Sarif, T, Pang, P.S, McHutchison, J.G, Afdhal, N, Charlton, M, Samuel, D, Gane, E
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial

G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial

by Manns, M, Forns, X, Samuel, D, Denning, J, Arterburn, S, Brandt-Sarif, T, Dvory-Sobol, H, Pang, P.S, McHutchison, J.G, Gane, E, Mutimer, D
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV

P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV

by Sarrazin, C, Dvory-Sobol, H, Svarovskaia, E.S, Doehle, B, Martin, R, Zeuzem, S, Lawitz, E, Hyland, R, Pang, P.S, Knox, S, Gane, E, Reddy, R, Afdhal, N, Mizokami, M, Omata, M, Miller, M.D, Mo, H, Bourlière, M
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

242 Exploratory Analysis of 30-day Emergency Department Revisits and Readmissions by Heart Failure Patients

242 Exploratory Analysis of 30-day Emergency Department Revisits and Readmissions by Heart Failure Patients

by Sauser, K, Pang, P.S, Schneider, D, Bonow, R.O
Published in Annals of emergency medicine (2011)

Get full text

Journal Article

O14 USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV

O14 USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV

by Osinusi, A, Townsend, K, Nelson, A, Kohli, A, Gross, C, Polis, M.A, Pang, P.S, Symonds, W.T, Talwani, R, Sajadi, M.M, Hogan, J, Benator, D, Subramanian, M, Mchutchison, J, Masur, H, Kottilil, S
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

by Kowdley, K.V, Stuart, G.C, Reddy, R.K, Rossaro, L, Bernstein, D.E, An, D, Svarovskaia, E.S, Hyland, R.H, Pang, P.S, Symonds, W.T, Mchutchison, J.G, Muir, A.J, Pockros, P.J, Pound, D, Fried, M.W
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

by Afdhal, N, Reddy, R.K, Pockros, P, Di Bisceglie, A.M, Arora, S, Yang, J.C, Dvory-Sobol, H, Zhu, Y, Pang, P.S, Symonds, W.T, McHutchison, J.G, Sulkowski, M.S, Kwo, P
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

by Mangia, A, Marcellin, P, Kwo, P, Foster, G.R, Buti, M, Bräu, N, Muir, A, Yang, J.C, Mo, H, Ding, X, Pang, P.S, Symonds, W.T, McHutchison, J.G, Zeuzem, S, Afdhal, N
Published in Journal of hepatology (01.04.2014)

Get full text

Journal Article

P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study

P0857 : 98% SVR12 in Korean and Taiwanese patients with chronic genotype 1 HCV infection receiving 12 weeks of ledipasvir/sofosbuvir: Results from an international, multicenter phase 3 study

by Lim, Y.-S, Chuang, W.-L, Ahn, S.-H, Peng, C.-Y, Paik, S.-W, Chien, R.-N, Chu, C.-J, Yang, J.C, Mo, H, Gao, B, Pang, P.S, Knox, S.J, McHutchison, J.G, Lee, Y.-J, Chang, T.-T, Jeong, S.-H, Han, K.-H, Kao, J.-H
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin

P0786 : 100% SVR12 with ledipasvir/sofosbuvir±ribavirin for 12 weeks in Japanese patients with chronic genotype 1 hepatitis C virus who previously failed therapy with protease inhibitor + pegylated interferonα + ribavirin

by Omata, M, Takehara, T, Yokosuka, O, Sakamoto, N, Korenagai, M, Mochizuki, H, Nakane, K, Enomoto, H, Yanase, M, Toyoda, H, Ikeda, F, Genda, T, Umemura, T, Yatsuhashi, H, Ide, T, Toda, N, Nirei, K, Ueno, Y, Nishigaki, Y, De-Oertel, S, Gao, B, Dvory-Sobol, H, Ishizaki, A, Omote, M, Pang, P.S, Knox, S.J, Symonds, W.T, McHutchison, J.G, Izumi, N, Mizokami, M
Published in Journal of hepatology (01.04.2015)

Get full text

Journal Article

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

by Thompson, A, Han, S, Shiffman, M.L, Rossaro, L, Ghalib, R, Beavers, K, Pianko, S, Wu, X, Pang, P.S, Rossi, S, McHutchison, J, Muir, A, Lee, S, George, J
Published in Journal of hepatology (01.04.2013)

Get full text

Journal Article